(Total Views: 663)
Posted On: 08/01/2020 12:07:48 PM
Post# of 154045
Re: bigtimerDC #46549
BigtimerDC
It seems to me premature do presume that the outcome data will not be significant, apparently we feel the scoring system is too subjective, that mild patients get well too easily without Leronlimab, and that it has taken (in investors opinions) too long for data to be released.
The graduated scoring system is devised to differentiate among the degree to which patients get better on the four separate parameters. The markedly higher incident of adverse and severe adverse events in placebo arm argues that there is not uniform improvement.
The board has talked extensively about long-haulers, who clearly were not completely resolved at 14 days.
I posted yesterday an article citing Wuhan data evaluating 1007 mild/moderate patients.
71.5% recovered or had stable condition
22% progressed to severe
2.2% professed to critical
4.3% died
It is undoubtedly more difficult do differentiate the clinical response to Leronlimab versus placebo in mild and moderately ill patient. Thus, Cytodyn in conjunction with the FDA adopted the graduated scoring system is devised to differentiate among the degree to which patients get better on the four separate parameters.
Additionally, there are 12 secondary outcome measures and 4 additional measures (chest x-rays, the chemokines and CCR5 receptor occupancy identified by Dr. Patterson).
I am optimistic. My concerns are only related to the political environment and difficulty standing out in a crowded field. Once full data are disclosed, all these concerns will fall away.
It seems to me premature do presume that the outcome data will not be significant, apparently we feel the scoring system is too subjective, that mild patients get well too easily without Leronlimab, and that it has taken (in investors opinions) too long for data to be released.
The graduated scoring system is devised to differentiate among the degree to which patients get better on the four separate parameters. The markedly higher incident of adverse and severe adverse events in placebo arm argues that there is not uniform improvement.
The board has talked extensively about long-haulers, who clearly were not completely resolved at 14 days.
I posted yesterday an article citing Wuhan data evaluating 1007 mild/moderate patients.
71.5% recovered or had stable condition
22% progressed to severe
2.2% professed to critical
4.3% died
It is undoubtedly more difficult do differentiate the clinical response to Leronlimab versus placebo in mild and moderately ill patient. Thus, Cytodyn in conjunction with the FDA adopted the graduated scoring system is devised to differentiate among the degree to which patients get better on the four separate parameters.
Additionally, there are 12 secondary outcome measures and 4 additional measures (chest x-rays, the chemokines and CCR5 receptor occupancy identified by Dr. Patterson).
I am optimistic. My concerns are only related to the political environment and difficulty standing out in a crowded field. Once full data are disclosed, all these concerns will fall away.
(6)
(0)
